Hims & Hers Stock Surges After FDA Schedules July Peptide Compounding Review
Hims & Hers shares rose 13.7% on April 13 after the FDA scheduled a July 23-24 advisory meeting to review seven peptides for compounding, including BPC-157 and TB-500. A favorable outcome could open a multi-hundred-million-dollar peptide market for the firm, though critics warn safety concerns and regulatory delays persist.
1. FDA Meeting Announcement
The FDA has set a Pharmacy Compounding Advisory Committee meeting for July 23-24 to evaluate adding seven peptides—including BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, and Epitalon—to its list of compounds that compounding pharmacies may produce.
2. Share Price Performance
Following the announcement, Hims & Hers stock closed up 13.7% on April 13 and then gained an additional 9.6% in premarket trading, reflecting investor optimism around expanded peptide offerings.
3. Growth Potential
Peptide therapies across metabolic health, anti-aging, and performance markets could represent a multi-hundred-million-dollar opportunity for the telehealth provider if compounding restrictions are eased, aligning with the company’s strategic focus on expanding its product pipeline.
4. Safety and Regulatory Concerns
While company leadership calls the review an important step toward legitimizing peptides, critics warn that non-binding recommendations, lingering safety questions, and a lengthy formal rulemaking process could delay or limit any market changes.